SCHEMBL2726410

SCHEMBL2726410

Fc1cc2c(N3CCOCC3)nc(Cl)nc2cc1Br

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.60
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 6/20 0.40
MAPT P10636 2/20 0.40
RAB9A P51151 1/20 0.39
POLB P06746 1/20 0.38
PRKDC P78527 2/20 0.38
PIK3CA P42336 2/20 0.38
MAPK1 P28482 4/20 0.37
GAA P10253 2/20 0.37
HPGD P15428 2/20 0.37
GLA P06280 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TSHR P16473 2/20 0.36
MAPK14 Q16539 1/20 0.36
MTOR P42345 1/20 0.36
KCNH2 Q12809 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16172467 0.79 SMN1; SMN2 (0.81) SMN1; SMN2ALDH1A1KDM4EMAPTPIK3CA
SCHEMBL4113454 0.78 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1KDM4EMAPTRAB9A
SCHEMBL2726311 0.78 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1KDM4EMAPTRAB9A
SCHEMBL9429952 0.78 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1KDM4EMAPTRAB9A
SCHEMBL9404419 0.78 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1KDM4EMAPTRAB9A
SCHEMBL3776763 0.75 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1KDM4EMAPTRAB9A
SCHEMBL17565791 0.75 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1KDM4EMAPTRAB9A
SCHEMBL2725733 0.75 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1PRKDCPIK3CAMTOR
SCHEMBL3780652 0.75 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1KDM4EPIK3CAMAPK1
SCHEMBL28371323 0.74 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1KDM4EMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160016952-A1 SUBSTITUTED AMINO-PYRIMIDINE DERIVATIVES ASANA BIOSCIENCES, LLC (US) 2016-01-21 US disclosed
US-20160016952-A1 SUBSTITUTED AMINO-PYRIMIDINE DERIVATIVES ASANA BIOSCIENCES, LLC (US) 2016-01-21 US disclosed
US-20160016952-A1 SUBSTITUTED AMINO-PYRIMIDINE DERIVATIVES ASANA BIOSCIENCES, LLC (US) 2016-01-21 US disclosed
US-9145411-B2 Substituted amino-pyrimidine derivatives ASANA BIOSCIENCES, LLC (US) 2015-09-29 US disclosed
US-9145411-B2 Substituted amino-pyrimidine derivatives ASANA BIOSCIENCES, LLC (US) 2015-09-29 US disclosed
US-9145411-B2 Substituted amino-pyrimidine derivatives ASANA BIOSCIENCES, LLC (US) 2015-09-29 US disclosed
US-9115092-B2 Substituted quinazoline and pyrido-pyrimidine derivatives ASANA BIOSCIENCES, LLC (US) 2015-08-25 US disclosed
US-9115092-B2 Substituted quinazoline and pyrido-pyrimidine derivatives ASANA BIOSCIENCES, LLC (US) 2015-08-25 US disclosed
US-9115092-B2 Substituted quinazoline and pyrido-pyrimidine derivatives ASANA BIOSCIENCES, LLC (US) 2015-08-25 US disclosed
US-20150011547-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES ASANA BIOSCIENCES, LLC (US) 2015-01-08 US disclosed
US-20130190492-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES ENDO PHARMACEUTICALS INC. (US) 2013-07-25 US disclosed
US-20130190492-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES ENDO PHARMACEUTICALS INC. (US) 2013-07-25 US disclosed
US-8440662-B2 Substituted quinazoline and pyrido-pyrimidine derivatives ENDO PHARMACEUTICALS, INC. (US) 2013-05-14 US disclosed
US-8440662-B2 Substituted quinazoline and pyrido-pyrimidine derivatives ENDO PHARMACEUTICALS, INC. (US) 2013-05-14 US disclosed
US-8440662-B2 Substituted quinazoline and pyrido-pyrimidine derivatives ENDO PHARMACEUTICALS, INC. (US) 2013-05-14 US disclosed
US-20120129851-A1 Substituted Quinazoline and Pyrido-Pyrimidine Derivatives ENDO PHARMACEUTICALS INC. (US) 2012-05-24 US disclosed
US-20120129851-A1 Substituted Quinazoline and Pyrido-Pyrimidine Derivatives ENDO PHARMACEUTICALS INC. (US) 2012-05-24 US disclosed
US-20120129851-A1 Substituted Quinazoline and Pyrido-Pyrimidine Derivatives ENDO PHARMACEUTICALS INC. (US) 2012-05-24 US disclosed
WO-2012058671-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES ENDO PHARMACEUTICALS INC. (US) 2012-05-03 WO disclosed
WO-2012058671-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES ENDO PHARMACEUTICALS INC. (US) 2012-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016952-A1 SUBSTITUTED AMINO-PYRIMIDINE DERIVATIVES MTOR, PIK3CA, AKT3 SMN1; SMN2 1345/4885ALDH1A1 3164/4885KDM4E 621/4885
US-20130190492-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES MTOR, PIK3CA, PDPK1 SMN1; SMN2 1256/4885ALDH1A1 3589/4885KDM4E 739/4885
US-20150011547-A1 SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES MTOR, PIK3CA, PDPK1 SMN1; SMN2 1256/4885ALDH1A1 3589/4885KDM4E 739/4885
US-20120129851-A1 Substituted Quinazoline and Pyrido-Pyrimidine Derivatives MTOR, PIK3CA, PDPK1 SMN1; SMN2 1256/4885ALDH1A1 3589/4885KDM4E 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.